H.C. Wainwright Global Life Sciences Conference (March 9-10, 2021 )
A fireside chat withSue Washer , President & Chief Executive Officer, will be available to view on-demand beginningTuesday, March 9, 2021 at7:00 a.m. ET through the entirety of the conference.
- 33rd Annual
ROTH Conference (March 15-17, 2021 )Ms. Washer andMark Shearman , Chief Scientific Officer, will participate in a fireside chat at1:00 p.m. ET onMonday, March 15, 2021 .
Audio webcasts of the presentation at the H.C. Wainwright and ROTH conferences can be accessed by visiting http://ir.agtc.com/events-and-presentations. A replay will be available on the Company's website following the events.
About AGTC
AGTC is a clinical-stage biotechnology company developing genetic therapies for people with rare and debilitating ophthalmic, otologic and central nervous system (CNS) diseases. AGTC is a leader in designing and constructing all critical gene therapy elements and bringing them together to develop customized therapies that address real patient needs. AGTC’s most advanced clinical programs leverage its best-in-class technology platform to potentially improve vision for patients with an inherited retinal disease. AGTC has active clinical trials in X-linked retinitis pigmentosa (XLRP) and achromatopsia (ACHM CNGB3 and ACHM CNGA3). Its preclinical programs build on the Company’s industry-leading AAV manufacturing technology and scientific expertise. AGTC is advancing multiple important pipeline candidates to address substantial unmet clinical need in optogenetics, otology and CNS disorders.
IR/PR CONTACTS:
David Carey (IR) or Glenn Silver (PR)
T: (212) 867-1768 or (646) 871-8485
david.carey@finnpartners.com or glenn.silver@finnpartners.com
Corporate Contacts:
Chief Financial Officer
T: (617) 843-5728
bsullivan@agtc.com
Chief Business Officer
T: (617) 413-2754
spotter@agtc.com
Source:
2021 GlobeNewswire, Inc., source